FDA's warning against B-Perfect
Upcoming SlideShare
Loading in...5
×
 

FDA's warning against B-Perfect

on

  • 299 views

On 05th June 2014, the Food and Drug Administration (FDA) is advising consumers not to purchase or use “B-Perfect”. ...

On 05th June 2014, the Food and Drug Administration (FDA) is advising consumers not to purchase or use “B-Perfect”.
B-Perfect is a product promoted and sold for weight loss on www.icanb-perfect.com and possibly sold in some retail stores.
FDA laboratory analysis confirmed that B-Perfect contains Sibutramine and Phenolphthalein.

Statistics

Views

Total Views
299
Views on SlideShare
297
Embed Views
2

Actions

Likes
0
Downloads
0
Comments
0

2 Embeds 2

https://twitter.com 1
http://www.slideee.com 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

FDA's warning against B-Perfect FDA's warning against B-Perfect Presentation Transcript

  • FDA’s warning againstFDA’s warning against ““B-PerfectB-Perfect”” Dr. P.NaiNa MohaMeD PharMacologist
  • IntroductionIntroduction On 05th June 2014, the Food and Drug Administration (FDA) is advising consumers not to purchase or use “B-Perfect”. B-Perfect is a product promoted and sold for weight loss on www.icanb-perfect.com and possibly sold in some retail stores. FDA laboratory analysis confirmed that B-Perfect contains Sibutramine and Phenolphthalein. Sibutramine is a controlled substance and it was removed from the market in October 2010 for safety reasons.  Phenolphthalein is a chemical that is not an active ingredient in any approved drug in the United States. Studies have indicated that it presents a cancer-causing risk.
  • PossiblePossible Mechanism of actionMechanism of action
  • RisksRisks ofof Slim Trim USlim Trim U
  • ContraindicationsContraindications ofof B-PerfectB-Perfect (Sibutramine)(Sibutramine) • B-Perfect should not be used by the patient who has.. History of cerebrovascular disease (stroke or transient ischemic attack) History of congestive heart failure History of coronary artery disease (eg, angina, myocardial infarction) History of cardiac arrhythmias History of peripheral arterial occlusive disease Uncontrolled hypertension. Major eating disorders, major (eg, anorexia nervosa or bulimia nervosa) Concomitant use with MAOIs Concomitant use with other centrally acting weight loss drugs
  • SeriousSerious Drug InteractionsDrug Interactions
  • Interaction withInteraction with AntidepressantsAntidepressants
  • Interaction withInteraction with NSAIDsNSAIDs
  • Interaction withInteraction with DecongestantsDecongestants
  • Interaction withInteraction with CYP3A4 InhibitorsCYP3A4 Inhibitors
  • FDA WarningsFDA Warnings • FDA warns the Consumers should stop using this product immediately and throw it away.  • FDA advises the Consumers who have experienced any negative side effects should consult a health care professional as soon as possible.  • FDA announces to the public of a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals.  These products are typically promoted for sexual enhancement, weight loss, and body building, and are often represented as being “all natural.”  • FDA claims that they are unable to test and identify all products marketed as dietary supplements on the market that have potentially harmful hidden ingredients.  • FDA advises the Consumers to exercise caution before purchasing any product in the above categories. 
  • FDA WarningsFDA Warnings FDA has requested market withdrawal after reviewing data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT).  SCOUT is part of a postmarket requirement to look at cardiovascular safety of sibutramine after the European approval of the drug.   The trial demonstrated a 16 percent increase in the risk of serious heart events, including non-fatal heart attack, non-fatal stroke, the need to be resuscitated once the heart stopped, and death, in a group of patients given sibutramine compared with another given placebo.  There was a small difference in weight loss between the placebo group and the group that received sibutramine.  RECOMMENDATION: Physicians are advised to stop prescribing Sibutramine (Meridia) to their patients, and patients should stop taking this medication.  Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforh
  • ReferencesReferences http:// www.fda.gov/Drugs/ResourcesForYou/Consumers/Buyin gUsingMedicineSafely/MedicationHealthFraud/ucm3999 35.htm? source=govdelivery&utm_medium=email&utm_source= govdelivery CURRENT Diagnosis & Treatment: Gastroenterology, Hepatology, & Endoscopy, 2e Norton J. Greenberger, Richard S. Blumberg, Robert Burakoff Clinician's Pocket Reference, 11e Leonard G. Gomella, Steven A. Haist Harrison's Online Featuring the complete contents of Harrison's Principles of Internal Medicine, 18e Basic & Clinical Pharmacology, 12e Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor
  • ReferencesReferences • http://www.micromedexsolutions.com • http://www.fda.gov/safety/medwatch/safetyi nformation/safetyalertsforhumanmedicalprod ucts/ucm228830.htm • http://www.tga.gov.au/safety/alerts- medicine-sibutramine-101008.htm • http://www.medsafe.govt.nz/hot/media/2010/ SibutramineOct2010.asp • http://www.bmj.com/content/340/bmj.c824